A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma-Reference-Cited by-同舟云学术

A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma

Published:2023-10-18 Issue:1 Volume:103 Page:185-198
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Merryman Reid W.^ORCID,Redd Robert A.,Freedman Arnold S.,Ahn Inhye E.,Brown Jennifer R.,Crombie Jennifer L.,Davids Matthew S.,Fisher David C.,Jacobsen Eric D.,Kim Austin I.,LaCasce Ann S.,Ng Samuel,Odejide Oreofe O.,Parry Erin M.,Isufi Iris,Kline Justin,Cohen Jonathon B.,Mehta-Shah Neha,Bartlett Nancy L.,Mei Matthew,Kuntz Thomas M.,Wolff Jacquelyn,Rodig Scott J.,Armand Philippe,Jacobson Caron A.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05475-0.pdf

Reference40 articles.

1. Sureda A, Zhang MJ, Dreger P et al (2018) Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer 124. https://doi.org/10.1002/cncr.31264

2. Evens AM, Vanderplas A, Lacasce AS et al (2013) Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 119. https://doi.org/10.1002/cncr.28243

3. Jacobson CA, Chavez JC, Sehgal AR et al (2022) Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23. https://doi.org/10.1016/S1470-2045(21)00591-X

4. Fowler NH, Dickinson M, Dreyling M et al (2022) Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28. https://doi.org/10.1038/s41591-021-01622-0

5. Budde LE, Sehn LH, Matasar M et al (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23:1055–1065. https://doi.org/10.1016/S1470-2045(22)00335-7

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Causal relationships between gut microbiota and lymphoma: a bidirectional Mendelian randomization study;Frontiers in Cellular and Infection Microbiology;2024-05-13